Last reviewed · How we verify
NCT03066297: OREX-IA
Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer
trial testing Extent of pulmonary resection in Stage IA Non-small Cell Lung Cancer in 1,018 participants. Participants enrolled and being followed up; not accepting new ones.
15 February 2027
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,018 |
| Start date | 15 February 2017 |
| Primary completion | 15 February 2027 |
| Estimated completion | 15 February 2027 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Extent of pulmonary resection
Conditions studied
- Stage IA Non-small Cell Lung Cancer — all drugs for Stage IA Non-small Cell Lung Cancer →
Sponsor
Samsung Medical Center
Who can join
Adults 18 to 75, any sex, with Stage IA Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigatros hypothesized that selection of surgical procedure according to the pre-defined institutional decision-making algorithm will not compromise the treatment outcomes including overall survival and disease-free survival in participants with clinical stage IA non-small cell lung cancer. The purpose of this study is to determine the outcome of participants with clinical stage IA NSCLC treated by 3 types of surgical resection (wide wedge resection, segmentectomy, or lobectomy) according to the institutional decision-making algorithm The investigators are planning to enroll 1,000 participants who meet the pre-defined eligibility criteria over 5 years.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Minimally Invasive Surgery in Non-Small Cell Lung Cancer: Where Do We Stand?
Berzenji L, Wen W, Verleden S, Claes E, et al · · 2023 · cited 8× · PMID 37686557 · DOI 10.3390/cancers15174281
Verify or expand the search:
- PubMed search for NCT03066297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03066297 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 6 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03066297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing